Nucleotide Sequence Discovery with TargetCker®
TargetCker® specializes in optimizing gene and target selection through a unique approach. Unlike existing methods, TargetCker® utilizes computational physics techniques to predict potential opening loops and seeding sites of mRNA. It then assesses spatial changes before and after therapeutic oligonucleotide binding, enabling speculation on the possibility of RNase binding. The current success rate of verification is exceptionally high at 40-60%. Additionally, we are developing platforms targeting the upregulation by targeting chromosomal DNA.
Chemistry Optimization with Curlona®
Curlona®, our chemical modification design tool, leverages significant computational improvements in our quantum mechanics tools. This allows us to compress standard calculations that would typically take over 25,000 hours into just 30 hours. As a result, Curlona® provides realistic modification permutations and estimates their effects on the stability and tissue specificity. Utilizing a molecular evolution algorithm and our proprietary data set of organ's nutritional preferences, Curlona® offers the possibility to design robust and tissue-specific therapeutic oligonucleotides.
Wet Lab Validation with ValiData
Finally, the designs generated by TargetCker® and Curlona® are synthesized and validated using the ValiData system, which are series of wet lab experiments from cellular potency test of ASOs, cellular toxicity test to animal PK and PD experiments. The collected data are then fed back into the TargetCker® and Curlona® processes, forming a closed loop of continuous improvement.
Our Pipeline Covering a Wide Range of Disease Areas
Leveraging the versatility of our TargetCker® and Curlona® platforms, our robust portfolio of pipelines encompasses a diverse array of disease areas, including metabolic diseases, cancer, CNS disorders, infection, and rare diseases.
